Gu Xiao-Pan, Wu Zhen, Jin Feng-Yu, Pan Bo, Zhao Yun-Fang, Li Jun, Zheng Jiao, Tu Peng-Fei
Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi. 2018 Jun;43(11):2339-2344. doi: 10.19540/j.cnki.cjcmm.20180323.001.
Pu-erh tea is a unique post-fermented tea processed from tender leaves of Camellia assamica. Characteristic component puerins were produced during the microbial fermentation process.This study focuses on the therapeutic effect and mechanism of puerinⅠ(P1) in Pu-erh tea on ApoE-/- mice with dyslipidemia and diabetes. It was found that P1 could significantly decreased total cholesterol (TC), triglyceride (TG) and fast blood glucose (FBG), and markedly improved impaired glucose tolerance (IPGTT) and insulin sensitivity (ITT) in hyperlipidemic and hyperglycemic ApoE-/- mice. Further experiments proved that P1 reduced FBG and plasma TG levels by inhibiting intestinal α-glycosidase enzymes activity and by activating low-density lipoprotein receptor respectively. This study confirmed the therapeutic effect and mechanism of P1 on ApoE-/- mice with diabetes and hyperlipidemia. Based on the good efficacy of this compound, P1 could be used as a new drug to treat the disorder of glycolipid metabolism.
普洱茶是一种由阿萨姆茶(Camellia assamica)的嫩叶加工而成的独特后发酵茶。特征性成分普洱菌素是在微生物发酵过程中产生的。本研究聚焦于普洱茶中的普洱菌素Ⅰ(P1)对患有血脂异常和糖尿病的载脂蛋白E基因敲除(ApoE-/-)小鼠的治疗作用及机制。研究发现,P1可显著降低高脂血症和高血糖的ApoE-/-小鼠的总胆固醇(TC)、甘油三酯(TG)和空腹血糖(FBG),并明显改善其糖耐量受损(IPGTT)和胰岛素敏感性(ITT)。进一步实验证明,P1分别通过抑制肠道α-糖苷酶活性和激活低密度脂蛋白受体来降低FBG和血浆TG水平。本研究证实了P1对患有糖尿病和高脂血症的ApoE-/-小鼠的治疗作用及机制。基于该化合物的良好疗效,P1可作为一种治疗糖脂代谢紊乱的新药。